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Purpose: To assess the long-term outcome of uveitis in juvenile idiopathic arthritis (JIA).
Design: Population-based, multicenter, prospective JIA cohort, with a cross-sectional assessment of JIA-
associated uveitis (JIA-U) 18 years after the onset of JIA.
Participants: A total of 434 patients with JIA, of whom 96 had uveitis, from defined geographic areas of
Denmark, Finland, Norway, and Sweden.
Methods: Patients with onset of JIA between January 1997 and June 2000 were prospectively followed for
18 years. Pediatric rheumatologists and ophthalmologists collected clinical and laboratory data.
Main Outcome Measures: Cumulative incidence of uveitis and clinical characteristics, JIA and uveitis
disease activity, ocular complications, visual outcome, and risk factors associated with the development of
uveitis-related complications.
Results: Uveitis developed in 96 (22.1%) of 434 patients with JIA. In 12 patients (2.8%), uveitis was diag-
nosed between 8 and 18 years of follow-up. Systemic immunosuppressive medication was more common among
patients with uveitis (47/96 [49.0%]) compared with patients without uveitis (78/338 [23.1%]). Active uveitis was
present in 19 of 78 patients (24.4%) at the 18-year visit. Ocular complications occurred in 31 of 80 patients
(38.8%). Short duration between the onset of JIA and the diagnosis of uveitis was a risk factor for developing
ocular complications (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.1e1.8). Patients with a diagnosis of
uveitis before the onset of JIA all developed cataract and had an OR for development of glaucoma of 31.5 (95%
CI, 3.6e274). Presence of antinuclear antibodies (ANAs) was also a risk factor for developing 1 or more ocular
complications (OR, 3.0; 95% CI, 1.2e7.7). Decreased visual acuity (VA) <6/12 was found in 12 of 135 eyes (8.9%)
with uveitis, and 4 of 80 patients (5.0%) with JIA-U had binocular decreased VA <6/12.
Conclusions: Our results suggest that uveitis screening should start immediately when the diagnosis of JIA
is suspected or confirmed and be continued for more than 8 years after the diagnosis of JIA. Timely systemic
immunosuppressive treatment in patients with a high risk of developing ocular complications must be considered
early in the disease course to gain rapid control of ocular inflammation. Ophthalmology 2020;-:1e11 ª 2020 by
the American Academy of Ophthalmology. This is an open access article under the CC BY license (http://creative
commons.org/licenses/by/4.0/).Supplemental material available at www.aaojournal.org.Juvenile idiopathic arthritis (JIA) is a chronic rheumatic
disease of unknown etiology that develops in children and
adolescents before the age of 16 years. Uveitis, inflamma-
tion of the uvea, is the most common extra-articular
manifestation in JIA.1,2 The reported occurrence of uveitis
in JIA varies considerably between different studies.3-5
Point prevalence is commonly reported between 10% and
15%.3,5,6 In a Finnish JIA cohort, the cumulative incidence
was 24% during the first 7 years of JIA,4 and in a Canadianª 2020 by the American Academy of Ophthalmology
This is an open access article under the CC BY license (http://creativecommons.o
rg/licenses/by/4.0/). Published by Elsevier Inc.cohort, 13% developed uveitis during a mean follow-up
time of 6.9 years.5 Both lower and higher occurrences of
uveitis in JIA are reported in other studies.7,8 Chronic
anterior uveitis is the most frequent type of uveitis
associated with JIA. Because of the asymptomatic nature
of JIA-associated uveitis (JIA-U), all children with JIA
should be routinely screened by an ophthalmologist.9 Early
identification and timely treatment of uveitis are crucial to
prevent complications that may lead to visual impairment1https://doi.org/10.1016/j.ophtha.2020.08.024
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Figure 1. Flowchart of the study population throughout the observation
period of 18 years. Total number of patients with juvenile idiopathic
arthritis (JIA) and JIA-associated uveitis (JIA-U) at baseline, 8-year, and
18-year follow-up visits.
Ophthalmology Volume -, Number -, Month 2020and, in some cases, blindness.10,11 Recently, evidence has
emerged for a treatment strategy for JIA-U, where early
introduction of immunomodulating treatment and rapid
control of the uveal inflammation aim to reduce the risk of
developing ocular complications and visual loss.12,13
There are few long-term prospective studies on uveitis in
JIA.4,14,15 Studies have shown that the majority of patients
with JIA-U develop uveitis within the first 4 years after
the onset of JIA5,16,17 and that high-grade uveitis and active
uveal inflammation are associated with higher complication
rates.11,13,18,19 At diagnosis, ocular complications are seen
in up to 21% to 76% of eyes with JIA-U,11,13 and further
complications are reported to occur during the course with
a complication rate of 0.33 per eye per year.18 However,
our knowledge is limited regarding long-term complica-
tions and complications in patients who develop uveitis late
in the course of JIA.14,16
Previous studies have reported that female gender, young
age at onset of JIA, oligoarticular JIA, and the presence of
antinuclear antibodies (ANAs) and human leukocyte antigen
(HLA)-B27 are risk factors for the development of uveitis in
JIA.3,5,20 Reported risk factors for ocular complications in
established uveitis are male gender, the onset of uveitis
before arthritis, short interval between the onsets of JIA and
uveitis, and the presence of ocular complications early in
the disease course.6,21 However, there are inconsistencies
between studies concerning risk factors of ocular
complications in JIA-U.
Our study describes the long-term clinical outcome in
JIA-U in terms of cumulative incidence, the use of immu-
nosuppressive treatment, visual outcome, ocular complica-




The Nordic JIA cohort is a prospective multicenter population-
based study with 12 participating centers from specific geographic
areas of Denmark, Finland, Norway, and Sweden. We included 510
consecutive patients with onset of JIA between January 1, 1997, and
June 30, 2000. Onset of JIA was defined as the first episode of
arthritis. Juvenile idiopathic arthritis was classified according to the
International League of Associations for Rheumatology criteria.22
To reflect a population-based sample, the study included all
referred children from defined catchment areas in each country.
During the inclusion period, letters were repeatedly sent to primary
healthcare providers, child health centers, and orthopedic, pediatric,
and rheumatology specialists in the catchment areas to ensure the
referral of all eligible patients.23 The healthcare systems in the
Nordic countries are mostly free of charge for children aged less
than 16 years, making it feasible to conduct a population-based
study. The baseline study visit took place at a median of 7
months (interquartile range [IQR], 6e8 months) after the onset of
JIA. Thereafter, at a median of 98 months, the 8-year follow-up
study took place, with 440 participants at this follow-up. All pa-
tients with a baseline visit were invited to the 18-year follow-up.
Among the 510 patients with a baseline inclusion, 434 were fol-
lowed for 18 years and 329 (75.8%) attended a study visit at a
department of pediatrics; of these, 273 (62.9%) attended a study
visit at a department of ophthalmology. The remaining 105 patients2
(24.2%) participated in the 18-year follow-up study through a
standardized telephone interview where we used the same
questionnaires as for the patients who attended the visit in person
(Fig 1). During the observation period, the patients were screened
for uveitis. For the first 2 years, the interval between the
ophthalmologic examinations was scheduled every 2 to 3 months;
thereafter, the intervals were longer depending on the time since
onset of JIA and JIA category. The screening followed local
programs based on international recommendations.9,10,24
Data Collection
Demographics, JIA and uveitis disease characteristics, and blood
samples were collected. Laboratory tests analyzed in this study
included HLA-B27, rheumatoid factor (RF), and immunofluores-
cence ANAs. Because no universal screening dilutions have been
established, ANA was considered positive according to the cutoff
value developed at the local laboratory related to the specific ANA
kits used. The cutoff value was 1/320 in Finland; 1/160 in
Copenhagen, Aarhus, and some parts of Sweden; and 1/80 in
Tromsø, Trondheim, and other parts of Sweden. Laboratory values
from disease onset were used but supplemented from the 18-year
visit in case of missing values.
For assessment of clinical remission in JIA, we applied Wallace
et al’s25,26 provisional criteria for inactive disease, requiring no
active arthritis, absence of systemic features due to JIA, normal
erythrocyte sedimentation rate or C-reactive protein, normal
global assessment on a visual analog scale from 0 to 10, absence
of active uveitis, and morning stiffness lasting 15 minutes. The
criterion for remission on medication is inactive disease on
medication for 6 successive months, and the criterion for
remission off medication is inactive disease for at least 12
months without treatment for JIA.
Characteristics of uveitis were recorded following the
Standardization of Uveitis Nomenclature (SUN) Working Group
criteria.27 The uveitis was recorded as an anterior, intermediate,
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disease. The course of uveitis was defined as acute, recurrent, or
chronic, as limited or persistent in duration, and as having a
sudden or insidious onset.27 The activity of uveitis in SUN
grades and intraocular complications were recorded at the 18-
year follow-up visit. Systemic medication was registered as pre-
vious if used in the period up to the 18-year follow-up and present
if used at the 18-year visit. Systemic medication included synthetic
disease-modifying antirheumatic drugs (sDMARDs) and biologic
disease-modifying antirheumatic drugs (bDMARDs).
Ophthalmologic Assessment
The 18-year ophthalmologic examination included measurement of
best-corrected visual acuities (BCVAs) monocular and binocular in
Snellen fraction with a Snellen chart or a letter or number chart. We
used the definition of visual impairment defined by the World
Health Organization:28 mild visual impairment as visual acuity
(VA) <6/12, moderate visual impairment as VA <6/18, severe
visual impairment as VA <6/60, and blindness as VA <3/60.
Slit-lamp examination was performed for assessment of uveitis
activity, which was defined as the presence of cells/mm2 field in
the anterior chamber, following the criteria of the SUN Working
Group.27 We defined uveitis course as acute if there was less than 3
months with uveitis activity and treatment, recurrent if there were
recurrent episodes and at least 3 months without uveitis activity
and treatment, and chronic if there was less than 3 months
without uveitis activity and treatment. Information on ocular
complications and ocular surgery was collected. We defined
glaucoma as pathologic cupping of the optic disc or visual field
defects in the presence of intraocular pressure >21 mmHg or
history of glaucoma surgery. In the case of missing information
in any variable, we excluded the patient from that particular
assessment.
Statistical Analysis
We used medians and IQRs to describe demographics and clin-
ical characteristics, and univariate logistic regression analysis
with odds ratios (ORs) to assess baseline variables as risk factors
of ocular complications in JIA-associated uveitis. Differences
between groups were analyzed using Pearson’s chi-square test
and 2-proportion z-test for dichotomized variables, and contin-
uous variables were analyzed using the ManneWhitney U test.
P < 0.05 was considered as significant. We performed a
KaplaneMeier analysis for the time interval between the onset of
JIA and the diagnosis of uveitis, where the dates of uveitis
diagnoses were obtained from the local screening programs.
Separate KaplaneMeier curves were constructed for patients
who had uveitis-associated ocular complications at 18 years and
patients without ocular complications at 18 years.
We constructed 2 heat maps. In the first, clinical characteristics
were plotted in rows and eyes in columns. By using hierarchical
clustering, rows and columns were ordered so that similar variables
appeared next to each other, and afterward the heat map was an-
notated in the lower panel with ocular complications. In the second
heat map, complications were plotted in rows and patients in col-
umns. After applying hierarchical clustering, the map was anno-
tated with previously reported risk factors for ocular complications
(Fig S1).6,21
We did not perform imputation for missing data, and we
included only patients with information on the assessed variable.
Statistical analyses were performed with Stata/MP version 15
(StataCorp LP, College Station, TX) and Wolfram (Champaign,
IL) Mathematica version 11.1.1.0.Ethical Approval and Consent to Participate
Written informed consent was obtained from all patients. The
medical research ethics committees and data protection authorities
in the respective participating countries approved the study. The
study was conducted according to the guidelines of the Declaration
of Helsinki.Results
At the 18-year follow-up, 96 (22.1%) of the 434 patients with
JIA had uveitis. The cumulative incidence of JIA-U was 44 of
143 (30.8%) in Finland, 22 of 111 (19.8%) in Denmark, 19 of
103 (18.4%) in Norway, and 11 of 77 (14.3%) in Sweden.
Finland had significantly more patients with JIA-U compared
with the other countries in the cohort (P ¼ 0.002, Pearson’s
chi-square).
Uveitis was detected in 89 of 440 patients (20.2%) during the
first 8 years of follow-up. Additionally, 12 patients (2.8%) were
diagnosed with uveitis between the 8-year20 and 18-year follow-
ups. Five patients with uveitis were lost to follow-up during this
period. Of the 96 patients with uveitis at the 18-year follow-up, 80
attended the ophthalmology visit (83.3%) (Fig 1). All patients who
were diagnosed with uveitis before JIA and 9 of the 12 patients
diagnosed with uveitis between the 8-year and 18-year follow-
ups were among the 80 patients with JIA-U examined by the
ophthalmologist.
The median age at the diagnosis of uveitis was 5.8 years (IQR,
3.8e11.7 years). The age at onset of JIA was lower for patients
with uveitis compared with those without uveitis (P ¼ 0.006,
ManneWhitney U test). For patients developing uveitis, the me-
dian time from the onset of JIA to the diagnosis of uveitis was 1.6
years (IQR, 0.4e5.0 years). The maximum time from the onset of
JIA to the diagnosis of uveitis was 17.6 years. Uveitis was
diagnosed before arthritis in 8 of 96 patients (8.3%). These 8 were
diagnosed with uveitis at a median of 0.3 years (IQR, 0.2e1.8
years) before the onset of JIA. The majority of patients with
uveitis, 59 of 96 (61.5%), were female (Table 1).
The distribution of uveitis in the different categories of JIA was
as follows: enthesitis-related arthritis in 14 of 45 patients (31.1%),
RF-negative polyarthritis in 21 of 71 patients (29.6%), psoriatic
arthritis in 8 of 28 patients (28.6%), extended oligoarthritis in 19 of
85 patients (22.4%), undifferentiated arthritis in 13 of 66 patients
(19.7%), and persistent oligoarthritis in 21 of 119 patients (17.6%).
We did not detect uveitis in any of the patients with RF-positive
polyarthritis or systemic-onset JIA.
We did not find any significant differences in gender or ANA
positivity among the patients with or without uveitis at the 18-year
visit. Human leukocyte antigen B27 was significantly more com-
mon in patients with uveitis than without (P ¼ 0.005, Pearson’s
chi-square) (Table 1). There was no significant difference in ANA
or HLA-B27 among the patients from Finland compared with the
other Nordic countries.
Clinical Presentation of Uveitis and Disease
Activity
Among the 80 patients with JIA-U who attended the 18-year
ophthalmology visit, 58 of 77 (75.3%) had bilateral uveitis, and
19 of 77 (24.7%) had unilateral uveitis. A total of 135 eyes in 77
patients were affected by uveitis. In 3 of the 80 examined patients,
the information regarding whether the uveitis was unilateral or
bilateral was missing. Anterior uveitis was found in 68 of 71 pa-
tients (95.8%). One patient had intermediate uveitis, and 2 patients
had panuveitis. Thirty-eight of 75 patients (50.7%) had a chronic3








n [ 96 P Value
Female, n (%) 297/434 (68.4) 238/338 (70.4) 59/96 (61.5) 0.096
Age at JIA onset, yrs 5.7 (2.6e9.8) 6.2 (2.9e10.1) 4.5 (1.9e8.7) 0.006
Age at uveitis diagnosis, yrs e e 5.8 (3.8e11.7)*
Age at 18-yr visit, yrs 23.4 (20.8e27.1) 23.5 (20.4e27.4) 21.6 (19.1e26.1) 0.003
Follow-up time, yrs 17.6 (16.7e18.4) 17.7 (16.8e18.6) 17.4 (16.5e18.2) 0.029
ANA positive, n (%) 142/384 (37.0) 101/291 (35.0) 41/93 (44.1) 0.103
HLA-B27 positive, n (%) 93/433 (21.5) 63/337 (18.7) 30/96 (31.3) 0.005
Cumulative joint count 7.0 (3.0e13.0) 6.5 (2.0e13.0) 8.5 (4.0e14.0) 0.027
Patient PA 0.5 (0.0e3.0)y 1.0 (0.0e3.5)z 1.0 (0.0e4.0)* 0.057
Patient GA 0.5 (0.0e2.5)y 0.5 (0.0e2.0)z 1.0 (0.0e3.0)* 0.013
JADAS27 1.0 (0.0e4.0)y 0.5 (0.0e3.5)z 2.0 (0.0e6.0)* 0.001
JIA categories, n (%)
Systemic JIA 14 (3.2) 14 (3.2) 0 e
Persistent oligoarthritis 119 (27.4) 98 (29.0) 21 (21.8) 0.087
Extended oligoarthritis 85 (19.6) 66 (19.5) 19 (19.9) 0.049
RF-negative polyarthritis 71 (16.4) 50 (14.8) 21 (21.9) 0.019
RF-positive polyarthritis 6 (1.4) 6 (1.4) 0 e
Psoriatic arthritis 28 (6.5) 20 (5.9) 8 (8.3) 0.026
Enthesitis-related arthritis 45 (10.4) 31 (9.2) 14 (14.6) 0.017
Undifferentiated arthritis 66 (15.2) 54 (15.7) 13 (13.5) 0.070
ANA ¼ antinuclear antibody; GA ¼ global assessment; HLA ¼ human leukocyte antigen; JADAS27 ¼ juvenile arthritis disease activity score based on
evaluation of 27 joints; JIA ¼ juvenile idiopathic arthritis; PA ¼ pain assessment; RF ¼ rheumatoid factor.
Values are median interquartile range (IQR) if not otherwise specified. P value for comparison of JIA with and without uveitis, by Pearson’s chi-square for
categoric variables, and ManneWhitney U test for continuous variables. Numbers assessed: *n ¼ 89, yn ¼ 403, and zn ¼ 315.
Self-reported pain on a visual analogue scale (range 0e10). Self-reported global assessment of well-being on a visual analogue scale (range 0e10).
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course. Nine of 75 patients (12.0%) had an acute course with
sudden onset and limited duration (<3 months) of the episode of
uveitis activity and treatment (Table 2). Six of the 9 patients with
acute course uveitis were HLA-B27 positive, and 5 patients had a
HLA-B27 positive enthesitis-related arthritis.
At the 18-year follow-up visit, there were no detectable cells in
the anterior chamber (SUN 0) in 59 of 78 (75.6%) of the assessed
patients with uveitis. Standardization of Uveitis Nomenclature
0.5þ to 1þ was found in 18 of 78 (23.1%) and SUN 2þ in 1 of 78
(1.3%) of the examined patients with JIA-U. None of the patients
had >SUN 2þ. Among the 19 patients with anterior chamber cells
at the visit, 13 (68.4%) had at least 1 ocular complication. A faint
flare (1þ) was found in 14 of 78 (17.9%), and a moderate flare
(2þ) was found in 4 of 78 (5.1%) of the examined patients with
uveitis (Table 2).
The proportion with active JIA disease according to the pro-
visional criteria reported by Wallace et al25,26 for inactive disease
was significantly higher in patients with JIA-U (45/86 [52.3%])
compared with those without uveitis (86/243 [35.4%]) (P ¼ 0.005,
Pearson’s chi-square). The rate of remission without medication
was lower among patients with uveitis (16/86 [18.6%]) compared
with patients without uveitis (100/243 [41.2%]) (P ¼ 0.005,
Pearson’s chi-square). The rate of remission on medication (inac-
tive disease, including the absence of active uveitis for at least 6
continuous months, while the patient is on medication) was higher
among patients with JIA-U, 14 of 86 (16.3%) compared with 23 of
243 (9.4%) for patients without uveitis, but this was not a signif-
icant difference (P ¼ 0.09, Pearson’s chi-square). Inactive disease
but not yet fulfilling remission criteria was found in 11 of 86
(12.8%) patients with JIA-U and in 34 of 243 (14.0%) of the pa-
tients with JIA without uveitis.4
Medication
At the baseline visit (median 7 months after onset of JIA), 25 of 96
(26.0%) of the patients with JIA-U were treated with synthetic
disease-modifying antirheumatic drugs (sDMARDs). sDMARDs
were used in 51 of 96 patients (53.1%) up to the 1-year visit
(median 13 months after onset of JIA) and in 72 of 96 patients
(75.0%) in the period up to the 8-year visit (median 98 months after
onset of JIA). None of the patients with JIA-U were taking
bDMARDs (infliximab or adalimumab) at baseline. Eight were
treated with bDMARDs (infliximab, n ¼ 7, adalimumab, n ¼ 1)
between the baseline and the 1-year visit, and 21 patients used
bDMARDs (infliximab, n ¼ 16, adalimumab, n ¼ 5) within 8 years
after onset of JIA.
Three of 8 patients with uveitis and ocular complications treated
with bDMARDs within the 1-year visit were diagnosed with
uveitis prior to JIA. Twelve of 21 patients treated with bDMARDs
within the 8-year visit were diagnosed with uveitis during the first
year after onset of JIA.
During the 18-year observation period, a total of 76 of 96
patients with uveitis (79.2%, 95% confidence interval [CI],
71.0e87.0) were treated with any sDMARDs compared with 223
of 378 patients without uveitis (59.0%, 95% CI, 54.0e64.0) (P
< 0.001, 2-proportion z-test). Any bDMARDs were given to 52 of
96 patients with uveitis (54.2%, 95% CI, 44.0e64.0) and 76 of 335
patients without uveitis (22.7%, 95% CI, 18.0e27.0) (P < 0.001,
2-proportion z-test). Table S1 (available at www.aaojournal.org)
shows detailed information on the different sDMARDs and
bDMARDs. Among the 19 patients with active uveitis at the 18-
year visit, 17 (89.5%) had been treated with sDMARDs or
bDMARDs at some point during the 18-year observation period.
Of the 59 patients with inactive uveitis (SUN 0) at the 18-year visit,
Table 2. Clinical Presentation of Juvenile Idiopathic
ArthritiseAssociated Uveitis According to the Standardization of
Uveitis Nomenclature
Clinical presentation Patients, n (%)
Uveitis localization, n ¼ 71
Anterior uveitis 68 (95.8)
Intermediate uveitis 1 (1.4)
Posterior uveitis 0
Pan uveitis 2 (2.8)
Uveitis symptoms, n ¼ 76
Mostly symptomatic 21 (27.6)
Mostly nonsymptomatic 55 (72.4)
Best judgment of onset of uveitis
episodes, n ¼ 72
Sudden onset 14 (19.4)
Insidious onset 58 (80.6)
Best judgment of the duration of uveitis episodes,
n ¼ 71
Limited duration (<3 months) 27 (38.0)
Persistent duration (3 months) 44 (62.0)
Uveitis course, n ¼ 75
Acute course (<3 mos with uveitis activity
and treatment)
9 (12.0)
Recurrent course (3 mos without uveitis
activity and treatment)
28 (37.3)
Chronic course (<3 mos without uveitis
activity and treatment)
38 (50.7)
Anterior chamber cells at the 18-yr follow-up,
n ¼ 78
SUN 0 (<1 cell in field) 59 (75.6)
SUN 0.5þ to 1þ (1e15 cells in field)* 18 (23.1)
SUN 2þ (16e25 cells in field) 1 (1.3)
Anterior chamber flare at the 18-yr follow-up,
n ¼ 78y
SUN 0 (none flare) 59 (75.6)
SUN 1þ (faint flare) 14 (17.9)
SUN 2þ (moderate flare) 4 (5.1)
SUN ¼ Standardization of Uveitis Nomenclature.
*Anterior chamber cells SUN 0.5þ to 1þ were grouped together in the
study database; thus, it is not possible to divide into 2 separate groups
(0.5þ and 1þ).
yNone of the patients had anterior chamber cells or flare SUN 3þ or
SUN 4þ.
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the observation period.
At the 18-year visit, 32 of 96 patients (33.3%) with uveitis were
treated with sDMARDs compared with 55 of 338 patients (16.3%)
without uveitis (P < 0.001, Pearson’s chi-square). Biologic
disease-modifying antirheumatic drugs were given to 34 of 96
(35.4%) of the patients with uveitis at the time of the visit and 50 of
338 (14.8%) of the patients without uveitis (P < 0.001, Pearson’s
chi-square). The use of any disease-modifying antirheumatic drugs
(DMARDs) was significantly more common among patients with
uveitis (47/96, 49.0%) at the 18-year visit compared with patients
without uveitis (78/338, 23.1%) (P < 0.001, Pearson’s chi-square)
(Table S1). In 33.7% of the patients with JIA-U uveitis was
reported to be the main reason for ongoing systemic
immunomodulating treatment. Local treatment with any eyedrops
were used by 29 of 92 (31.5%) of patients with JIA-U at the
visit. Among the 19 patients with active uveitis at the visit, 14
(73.7%) were using sDMARDs or bDMARDs. Of the 59 patients
with uveitis without active uveitis (SUN 0) at the 18-year visit, 29
(49.2%) had ongoing treatment with sDMARDs or bDMARDs.Among the patients who had registered ocular complications at
the 18-year visit, 6 of 31 (19.4%) used bDMARDs within 1 year of
follow-up compared with 1 of 59 (1.7%) of the patients
with uveitis who did not develop complications. This number was
13 of 31 (41.9%) and 5 of 59 (8.5%), respectively, within 8 years
of follow-up. Of the patients who had ocular complications at the
18-year visit, 25 of 31 (80.6%) had used bDMARDs at some point
during the 18-year observation period compared with 27 of 59
(45.8%) of the patients with uveitis who did not develop
complications.
Ocular Complications and Visual Acuity
We found 1 or more ocular complications in 31 of 80 patients
(38.8%) with uveitis attending the 18-year ophthalmology visit.
Forty-two of 135 (31.1%) uveitis eyes were affected by at least 1
complication (Table 3). The most frequent ocular complications
were cataract and glaucoma. Cataract was found in 25 of 80
(31.3%), of whom 21 of 25 (84.0%) had undergone cataract
surgery. Among the patients who had cataract surgery, 16
patients also had glaucoma, 10 had synechiae, 8 had macular
edema, 6 had band keratopathy, and 3 had epiretinal membrane,
hypotony, and phthisis. Glaucoma occurred in 22 of 80 patients
(27.5%), of whom 18 of 22 (82.0%) had undergone glaucoma
surgery. Fifteen patients underwent surgery for both cataract and
glaucoma. Four patients presented with an ocular complication at
the baseline visit, 20 patients developed at least 1 complication
during the first 8 years of follow-up, and 7 of the previously un-
affected patients developed a uveitis-related complication between
the 8-year and 18-year follow-up visits.
Eight patients were diagnosed with uveitis before JIA. All of
them developed a cataract, and 7 were also diagnosed with glau-
coma. In contrast, all patients with uveitis without ocular compli-
cations had their uveitis diagnosed after the onset of JIA. The
timepoint for uveitis diagnosis for patients without complications
was spread throughout the observation period, as presented in the
KaplaneMeier plots (Fig 2). An association was found between
ocular complications and the starting point of uveitis with a
median time of 0.4 years (IQR, 0.1e1.1 years) between the onset
of JIA and the diagnosis of uveitis for the patients who
developed ocular complications and 1.9 years (IQR, 0.5e4.1
years) for the patients who did not develop uveitis-related com-
plications (P < 0.001, ManneWhitney U test). Complications
were most frequent among patients with anterior uveitis (28/68;
41.2%), asymptomatic uveitis (24/55; 43.6%), and a chronic course
(23/38; 60.5%) or insidious onset of uveitis (27/58; 46.6%) (Fig 3).
In our cohort, 87.5% had been diagnosed with uveitis within 8
years after the onset of JIA (Fig 2). Among the 12 patients with
onset of uveitis between the 8-year and 18-year follow-ups, only
1 patient developed uveitis-related complications. The age at
uveitis diagnosis was available for 6 of the 12 patients (median age
22.9 years; IQR, 17.4e26.7 years). Four patients had persistent
oligoarthritis, 2 patients had extended oligoarthritis, 1 patient had
RF-negative polyarthritis, 1 patient had psoriatic arthritis, 1 patient
had enthesitis-related arthritis, and 3 patients had undifferentiated
arthritis. Nine patients were male, and 5 patients were HLA-B27
positive. Information on the clinical presentation of the uveitis
was available for 9 of the 12 patients. Four patients had acute
uveitis, 3 patients had recurrent uveitis, and 2 patients had chronic
uveitis. Five had symptomatic uveitis.
We found worst-eye visual impairment with monocular BCVA
<6/12 in 8 of 80 patients (10.0%) with uveitis examined by the
ophthalmologist at the 18-year follow-up visit. Four of these 8
patients had BCVA >6/12 when tested with both eyes open, and
thus binocular BCVA <6/12 in 4 of 80 patients (5.0%). Two
patients had no light perception in both eyes, and 3 patients had no5
Figure 2. Time for diagnosis of uveitis during the 18-year observation
period in the Nordic juvenile idiopathic arthritis (JIA) cohort for the
patients who developed and did not develop ocular complications. A,
KaplaneMeier curve for the time points for diagnosis of uveitis in the total
JIA cohort (black curve), patients with uveitis who did not develop ocular
complications (blue curve), and patients with uveitis who developed
ocular complications (red curve). Ocular complications were assessed at
the 18-year follow-up, and time points for diagnosis of uveitis were
collected from ophthalmological screening. B, Density histogram for the
onset time points of uveitis among the patients who remain complication
free, with each blue dot representing 1 uveitis case. C, Density histogram
for the onset time points of uveitis with ocular complications, with each
red dot representing 1 uveitis case.
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light perception in 1 eye (Table 3). Binocular BCVA <6/12 was
found in 4 of the 21 patients who had undergone cataract
surgery, and 2 of the patients who were blind at the 18-year visit
had both undergone cataract surgery.
Risk Factors Associated with Ocular
Complications
A short time interval between the onset of JIA and diagnosis of
uveitis, including both positive and negative values, was a signif-
icant risk factor for at least 1 complication related to uveitis in
univariate logistic regression (OR, 1.4; 95% CI, 1.1e1.8). Another
significant risk factor for ocular complications was ANA positivity
(OR, 3.0; 95% CI, 1.2e7.7). All 8 patients with a diagnosis of
uveitis before the onset of JIA developed cataract, and the risk of
glaucoma was high when uveitis was diagnosed before JIA (OR,
31.5; 95% CI, 3.6e274). We did not find any significant predictors
of ocular complications in analyses of gender, age at diagnosis of
uveitis, age at onset of JIA, different JIA categories, or uveitis
development 8 to 18 years after onset of JIA. The distribution of
ocular complications relative to these assessed variables is pre-
sented in the heat map in Fig S1 (available at www.aaojournal.org).Discussion
In our Nordic JIA cohort, enrolled from pediatric rheuma-
tology practices, the cumulative incidence of uveitis was
22.1% during the 18 years of 434 prospectively followed
patients with JIA. Uveitis-related complications occurred in
38.8%, and decreased VA <6/12 occurred in 12 of 135 eyes
(8.9%) with JIA-U.
The reported prevalence of uveitis in JIA varies consider-
ably between different studies and populations.4,6,9,14,15,29-35
Several studies presenting uveitis prevalence are retrospec-
tive or registry-based, with a broad range of follow-up times,
making it difficult to compare results. Other reasons for the
variability in reported uveitis prevalence are differences in
what is actually reported, such as point prevalence or period
prevalence, study design, cohort compositions such as referral
cohorts from which the patients are recruited, and genetic
differences between populations. Some of the highest preva-
lence is reported from the Nordic countries,3,4,20 and it has
been suggested that children with European descent,
especially with Nordic descent, have a higher risk of uveitis
in JIA.3,36 In other population-based studies from Spain,
Czech Republic, Germany, and Estonia, the cumulative inci-
dence of uveitis varied between 4.0% and 12.0%, but the
follow-up period in these studies were shorter than in our
study.31-35
The overall recently reported prevalence of uveitis
appears to be decreasing compared with the 1990s and
2000s.37,38 Kotaniemi et al38 reported a decrease in the
cumulative incidence of uveitis in JIA from 25.0% to
18.0% in 2 separate cohorts collected in 1990 to 1993 and
2000 to 2003. Likewise, Tappeiner et al37 reported a
decrease in uveitis from 33.6% to 23.9% between 2002
and 2013. In their study, the use of DMARDs was more
common in the more recent cohort. In a later publication,
they reported that methotrexate treatment started during
Figure 3. Heat map visualization of uveitis clinical characteristics per eye according to ocular complications. Uveitis clinical characteristics (rows) of each
eye (columns) are ordered so that similar variables appear next to each other. The heat map is annotated (lower panel) with ocular complications. Uveitis
characteristics; there is a cluster in orange to the left in the heat map consisting of eyes with persistent, chronic, nonsymptomatic, insidious, and anterior
uveitis. Most complications occur for eyes that belong to this group. The blue color consists of limited, acute, symptomatic, sudden, and nonanterior
(intermediate or pan) localization of the uveitis. The purple color is eyes with recurrent uveitis course. Ocular complications; black square represents each 1
eye with an ocular complication. L ¼ left eye; R ¼ right eye.
Rypdal et al  Uveitis in the Long-Term Perspective of JIAthe first year after the onset of JIA was associated with a
lowered risk of uveitis and that a combination treatment of
methotrexate and anti-tumor necrosis factor was associated
with an even lower risk of JIA-U.39 In our study, the
occurrence of uveitis remains high. This might partly be
explained by the slightly less common sDMARD
treatment in our study at the last study visit compared
with the study by Tappeiner et al37 and by the fact that
our patients had onset of JIA in 1997e2000 when
treatment with biologics was less common. SyntheticTable 3. Ocular Complications in Juvenile Idiopathic ArthritiseAssoc
the 18-Year Foll
Ocular complications









BCVA, binocular and monocular worst eye
Mild visual impairment 6/18  BCVA <6/12
Moderate visual impairment 6/60  BCVA <6/18
Severe visual impairment 3/60  BCVA <6/60
Blindness <3/60z
BCVA ¼ best-corrected visual acuity.
*Binocular.
yMonocular worst eye.
zOne patient with blindness had trauma to the eye.disease-modifying antirheumatic drug treatment was
ongoing at 18 years of follow-up in our study in 25.7% of
patients with JIA with or without uveitis, compared with
47.2% in the study by Tappeiner et al.37 Treatment with
bDMARDs was ongoing at the 18-year visit in our study
in 24.9% of patients, compared with 21.8% of patients in the
study by Tappeiner et al.37 The difference in the rate of
sDMARD treatment may be explained by the longer
follow-up time in our study. Remission of uveitis (in




Uveitis Eyes, n (%)
n [ 135
31 (38.8) 42 (31.1)
25 (31.3) 32 (23.7)
22 (27.5) 30 (22.2)
14 (17.5) 19 (14.1)
8 (10.0) 9 (6.7)
7 (8.8) 9 (6.7)
3 (3.8) 4 (3.0)
3 (3.8) 4 (3.0)
3 (3.8) 4 (3.0)
1 (1.3),* 2 (2.5)y 3 (2.2)
1 (1.3),* 2 (2.5)y 3 (2.2)
0,* 1 (1.3)y 1 (0.7)
2 (2.5),* 3 (3.8)y 5 (3.7)
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patients (75.6%) compared with 42.0% in the study by
Kotaniemi et al38 and 65.3% by Tappeiner et al.37
In our study, the median time from the onset of JIA to the
diagnosis of uveitis was 1.6 years, whereas some previous
studies report a mean time of 1.1 to 1.8 years and a median
time of 5.5 months.4,5,9 Moreover, among study participants
diagnosed with uveitis, 8.3% developed uveitis before JIA,
and 80.0% had uveitis within 4 years after the onset of JIA.
Uveitis reportedly develops before JIA in 3% to 7%3,30 and
during the first 4 years after onset of JIA in up to 91%.4,5,9
These discrepancies with other studies may be explained by
different definitions of the onset date of JIA. In our study,
this was not the date of the physician’s diagnosis of
arthritis, but the date of the first evident clinical sign of
arthritis, such as an obvious swelling or limp, even if
reported the first time by the patients/parents and only
later confirmed by a physician.
In contrast to most recent studies suggesting that uveitis
rarely develops more than 7 years after the onset of JIA,4,5,9
12.5% of the patients with JIA-U in our cohort had onset of
uveitis after the 8-year follow-up. Our results are in line with
those of Zak et al,14 who reported an increase in uveitis
occurrence and complications from 1979 to 1980 to 1996
to 1997. Our study suggests that continuing the uveitis
screening in patients with JIA after 7 to 8 years of
diagnosis might be beneficial because approximately half
of the late uveitis cases were asymptomatic. A lack of
previous long-term prospective cohort studies may have
led to an underestimation of the number of late uveitis cases
and the overall cumulative incidence of uveitis.5,13 Other
prospective, long-term follow-up studies are needed to
better assess the risk of late onset of uveitis in JIA.
In our study, 38.8% of the patients with JIA-U developed
at least 1 ocular complication during the 18 years of
observation. The rate of complications is lower than in
previous reports 2 or more decades ago.15,16,40 However,
complications are more prevalent in our study compared
with other recent studies from Europe.37-39 Kotaniemi
et al38 presented an overall ocular complication rate of
21.0% in 2000e2003. The German prospective study by
Tappeiner et al37 found a decrease in ocular complications
from 33.6% to 23.9% in the period between 2002 and
2013. Our high prevalence of complications might be
explained mainly by the long follow-up because 7 of 31
(22.6%) of the ocular complications occurred in the period
between 8 and 18 years of follow-up.15,16,37,38,40 Earlier
studies have shown that both treatment with synthetic and
biologic DMARDs, and low uveitis activity are associated
with lower occurrence of poor vision and ocular
complications.11,18,19,39 The comparatively high
complication prevalence in our study may be explained
partly by the recruitment period in the era before the early
start of bDMARDs was an established treatment strategy.
In our study, complications are more common in the
group of patients who are diagnosed with uveitis before or
shortly after onset of JIA. For patients who develop
complications, the use of bDMARDs increased from 16%
to 77% from 1 year to 18 years after the onset of JIA.
However, most of our patients (75.6%) had quiescence of8
uveitis with no detectable cells in the anterior chamber at
the 18-year visit.
In general, comparisons of studies on uveitis-related
complications are challenging because of selection bias.
Studies with shorter follow-up time may underreport the rate
of complications, whereas studies from retrospective tertiary
centers may report a higher rate of complications because
they include the more severe uveitis cases. Cohorts selected
from tertiary ophthalmology clinics may have more ocular
complications than those collected from pediatric rheuma-
tology centers. On the other hand, in many Nordic countries,
tertiary pediatric rheumatology centers and tertiary
ophthalmology clinics are often located at the same hospital,
meaning that the selection of patients will not differ. In
short, early introduction of DMARDs as a strategy for
treatment of arthritis seems to reduce both the risk of uveitis
and its complications.39 Well-established ophthalmologic
screening programs9,10 may also contribute to the reduced
ocular complications, presumably by earlier diagnosis
before complications have occurred and timely treatment
of the ocular inflammation. We did not find a significant
association between the development of ocular
complications and male gender or young age at the onset
of uveitis.21,41 However, we confirmed that developing
uveitis before JIA, having a short duration between onset
of JIA and diagnosis of uveitis, and having ANA
positivity are risk factors for developing ocular
complications. Notably, all patients who developed uveitis
before JIA had ocular complications.
Long-term poor visual outcome has been associated with
a diagnosis of uveitis before JIA, short interval between the
diagnosis of arthritis and uveitis, high-grade uveal inflam-
mation, and the presence of ocular complications early in
the disease course and history of intraocular surgery.6,11,13,21
Despite a relatively high rate of complications, the
proportion of patients with unfavorable visual outcome in
our study was lower or in line with previous
reports.2,4,17,40 Haasnoot et al17 found in their study from
2016 that 4% had a visual impairment or were legally
blind (20/200) at the age of 18 years and that 33% had
at least 1 eye with VA 20/50. In our study, 2.5% of the
patients with JIA-U were blind in both eyes and 3.8%
were blind in the worst eye, and 5.0% in our study had a
binocular VA <6/12. Kotaniemi et al4 found that 3 of 104
children (2.9%) with JIA-U had a VA 20/60 after a
mean follow-up time of 4.5 years, whereas we found a
BCVA <6/18 for both eyes in 3 patients (3.8%) and in the
worst eye for 6 patients (7.5%) after a median follow-up
time of 17.6 years.
Study Strengths and Limitations
There are several strengths of this study. To our knowledge,
this is one of few long-term prospective population-based
studies on JIA-associated uveitis. This means that our
results are generalizable to patients in the population with
JIA, not just the patients with more severe JIA-U who are
usually managed at tertiary ophthalmology centers. Despite
the long observation period of 18 years, the proportion of
patients lost to follow-up is relatively small, and we have
Rypdal et al  Uveitis in the Long-Term Perspective of JIAreliable ophthalmologic data for 83% of the patients with
uveitis 18 years after JIA onset. The study is conducted
according to the International League of Association for
Rheumatology classification, the American College of
Rheumatology disease activity criteria, and the SUN
Working Group criteria, enabling comparison with other
studies in the field. A limitation of the study is that we do
not have information on the precise timepoints when
patients started topical corticosteroids, the treatment starting
point, or the indication (arthritis or uveitis) for treatment
with systemic corticosteroids or DMARDs. Also, the
inclusion period of the study was at the beginning of the
biologic era. Thus, it may not reflect the effect of early
implementation of immunomodulating treatment on uveitis
outcomes. At the 18-year visit, 15% were lost to follow-up,
and because patients with more severe disease are likely to
attend follow-ups, this may lead to biases and an over-
estimation of the cumulative uveitis incidence. For instance,
the cumulative incidence of uveitis may be 96 of 510
(18.8%) rather than 96 of 434 (22.1%) if all uveitis cases
attended the 18-year follow-up. On the other hand, we may
also have lost some late diagnosed uveitis cases, which
implies that the true cumulative incidence might be
somewhere between those figures. There is some missing
information for specific uveitis variables, reducing the total
number of assessable patients. The relatively small sample
size in subgroups may limit identification of relevant risk
factors for complications. Future work should focus on
longer follow-up and developing prediction rules for pre-
diction of severe uveitis course to enable targeted screening
and treatment strategies adapted to high-risk subgroups.
In conclusion, this unique long-term prospective
population-based study found that a considerable proportion
of patients with uveitis still develop sight-threatening com-
plications in young adulthood. The patients at highest risk of
complications are those who develop uveitis before JIA or
closely after the onset of JIA. Screening by an ophthalmologist
must start urgently in all children when JIA is suspected and
diagnosed. Our study shows that uveitis may develop up to 18
years after the onset of JIA. We suggest screening to be
extended for a longer period than recommended in most
established screening programs to identify late-onset uve-
itis.9,10,12 The high prevalence of uveitis and ocular
complications emphasizes the need for interdisciplinary care,
with early consideration of systemic immunosuppressive
treatment. Ophthalmologists and pediatric rheumatologists
should collaborate closely to minimize the risk of visual
impairment with potentially severe implications for quality
of life in young adults with JIA.References
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